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Introduction
Factor XI (FXI) is an integral component in the coagulation cascade. Upon contact activation of the intrinsic pathway of the coagulation cascade, the zymogen form of FXI is activated by FXIIa to form the enzymatically active form FXIa. FXIa in turn cleaves and activates its physiological substrate, FIX, which ultimately leads to thrombin generation and clot formation (Gailani et al., 2015) . FXI is a dimer composed of identical 80 KDa subunits, and each subunit starting from the N-terminus consists of four apple domains (A1-A4) and a catalytic domain.
Multiple lines of evidence have demonstrated a crucial role for FXI in thrombus formation, with a relatively small contribution to hemostasis (Duga and Salomon, 2013) . Human genetics and epidemiological studies showed that severe FXI deficiency (hemophilia C) confers a reduced risk of ischemic stroke and deep vein thrombosis, whereas increased levels of FXI are associated with a higher risk for venous thromboembolism (VTE) and ischemic stroke (Duga and Salomon, 2013; Gailani et al., 2015) . Likewise, preclinical models of FXI deficiency demonstrated profound protection from both arterial and venous thrombosis (Wang et al., 2005; Wang et al., 2006) , as well as ischemic brain injury (Kleinschnitz et al., 2006) . Furthermore, a recent phase 2 clinical study revealed superior antithrombotic efficacy for the prevention of VTE in patients undergoing total knee arthroplasty treated with FXI antisense oligonucleotide (ASO) compared with enoxaparin (an indirect inhibitor of FXa) (Buller et al., 2015) .
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5 from ischemic stroke (Kleinschnitz et al., 2006; Salomon et al., 2008) cerebral MES and demonstrated the therapeutic benefits of both clopidogrel and aspirin (Zhou et al., 2016a) . (Markus et al., 2005; Wong et al., 2010) . Since there was no evidence available for the effects of anticoagulants on MES, we used apixaban, a small molecule inhibitor of FXa, as a tool compound and demonstrated its protection from MES and thrombotic events in this rabbit cerebral MES model (Zhou et al., 2016b ).
In the current study, we investigated the effects of a potent and selective small molecule inhibitor was fixed by a flexible-arm magnetic-base holder (McMaster-Carr, Princeton, NJ, USA) at the posterior end of zygomatic bone of the rabbits, at an angle of ~80 degree against the buccal surface. The MCA was insonated at a depth between 19 to 22 mm as described in detail previously (Zhou et al., 2016a) . MES (defined as High Intensity Transient Signals, HITS) was recorded and confirmed based on the criteria defined by the International Consensus Committee (Ringelstein et al., 1998; Symposium, 1995) as described previously (Zhou et al., 2016a ) (Zhou et al., 2016b .
Bleeding time was recorded when bleeding ceased, with a maximal bleeding time set for 30 min.
Three nail cuticles per rabbit were measured, and an average of the bleeding time from the three cuticles was considered as one data point.
Drug Administration
The FXIa inhibitor Compound 1 (structure shown in Fig. 1) , with a molecular weight of 596.6
Daltons, was synthesized following the procedures described in detail previously (International Publication Number WO 2011/100401 A1) at Merck Research Laboratories (Kenilworth, NJ, USA). Table 1 summarizes the potency and selectivity parameters (details on Methods described in the following section) of the compound.
For the efficacy study (i.e., the 30% FeCl 3 -induced carotid arterial thrombosis and cerebral MES study described above), various doses (0-3 mg/kg/h) of Compound 1 or vehicle (35% hydroxypropyl β-cyclodextrin in 10 mM phosphate buffer, pH 7.0) were continuously infused at 2 mL/kg through the marginal ear vein. The i.v. dosing started 60 min prior to vessel injury and ended upon study completed. A dose of 5 mg/kg/h Compound 1 was infused for the cuticle bleeding study; otherwise the dosing regimen was the same as that which was used for the efficacy studies. This dosing regimen for Compound 1 was predicted to accomplish sufficient exposures in our study based on a previous internal standard pharmacokinetics study in rat (not shown), and validated in selected time points in the current rabbit MES and cuticle bleeding models under current dosing regimen. Apixaban (a FXa inhibitor, synthesized at Merck; (Zhou et al., 2016b) ) at 3 mg/kg/h, i.v., was used as a control for the cuticle bleeding study.
In Vitro Protease Inhibition Assays
This article has not been copyedited and formatted. The final version may differ from this version. phase B solution was used to elute the column. Plasma drug exposure for apixaban was analyzed as described previously (Zhou et al., 2016b) .
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Results
Effect of Compound 1 on cerebral MES induced by carotid arterial thrombosis in rabbits
Compound 1 dose-dependently inhibited thrombus formation in the carotid artery and MES incidence in the MCA induced by 30% FeCl 3 injury of the carotid artery in rabbits (Fig. 2) . The integrated blood flow (AUC, illustrated as % of blood flow relative to baseline) was increased from 57.2 ± 7.7% in vehicle group (n=9), to 90.6 ± 3.6% for the 3 mg/kg/h Compound 1 group Ex vivo PT and aPTT analysis confirmed pharmacodynamic responses for Compound 1 ( Fig. 3B and C). Compound 1 significantly elevated aPTT, with 86.6 ± 9.8% (p<0.001) and 220.3 ± 10.3%
(p<0.001) increase at 1 hour, and 78.7 ± 15.0% (p<0.001) and 290.4 ± 10.9% (p<0.001) increase at 2 hours post treatment with 0.3 and 3 mg/kg/h, i.v., respectively, vs. vehicle (Fig. 3B ). In contrast, Compound 1 had no effects on PT (Fig. 3C ). significantly prolonged the bleeding time (291% increase over the vehicle, p<0.001, n=8).
Plasma drug analysis confirmed the expected drug exposure for both Compound 1 and apixaban upon the rabbit nail cuticle transection (i.e., 60 min after i.v. infusion) (Fig. 5B) . Likewise, ex
This article has not been copyedited and formatted. The final version may differ from this version. (Buller et al., 2015) .
Anticoagulation with vitamin K antagonists (VKA) has been the gold standard for stroke prevention in atrial fibrillation (SPAF) for decades. However, management of VKA therapy is complicated due to the narrow therapeutic index, slow onset and offset of action, and numerous dietary and drug interactions. In recent years, a new class of non-vitamin K antagonist oral anticoagulants (NOACs; including direct thrombin receptor inhibitor dabigatran, and FXa inhibitors such as rivaroxaban and apixaban) were approved for SPAF based on their similar or superior benefit-risk profiles compared to warfarin (Granger et al., 2011; Lin et al., 2015; Morais and De Caterina, 2016) . Nevertheless, NOACs are still associated with a significant bleeding risk.
Therefore, there is a need for novel anticoagulants that confer non-inferior efficacy with significantly reduced bleeding liability for the treatment of SPAF. FXI blockade mechanisms may meet those criteria and thus may have promising therapeutic potential for SPAF.
In this work, we describe the use of Compound 1, a small molecule inhibitor of FXIa, in a rabbit model of cerebral MES. Compound 1 achieved full efficacy in both arterial thrombosis and cerebral MES at 3 mg/kg/h, i.v. (Fig 2) , which was similar to that of 0.5 mg/kg/h apixaban, i.v., in this rabbit model (Zhou et al., 2016b) . The ED 50 for Compound 1 on inhibition of thrombus JPET #238600
1 8 similar bleeding model was used in these two studies, some variables still exist, such as different operators, laboratories, and animal sources. It also should be pointed out that the doses used for these two bleeding studies are not the same, and a full dose-dependent response might be needed.
Overall, cross-validation of the model might be helpful to understand the differences.
Nevertheless, from plasma drug exposure perspective, our data appear in agreement with clinical observation for apixaban since 3 mg/kg/h apixaban in rabbit achieved ~ 75x antithrombotic ED 50 plasma exposure vs. ~ 69x peak plasma levels in clinic (Frost et al., 2014) .
In summary, our study demonstrated a dose-dependent inhibition of Compound 1 on both arterial thrombosis and MES. Pharmacokinetic and pharmacodynamic analyses demonstrated an excellent correlation between Compound 1 plasma drug exposure and efficacy, as well as aPTT.
Our data showed that adequate doses of Compound 1 may achieve maximal reduction of MES, but with significantly less bleeding liability compared to apixaban as defined by the cuticle bleeding model. Thus, FXIa blockade may provide a promising new therapeutic approach for the treatment of thrombotic diseases such as SPAF.
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